Literature DB >> 16937543

Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report.

M Isabel Lucena1, Raúl J Andrade, Luis Vicioso, F Jesús González, Ketevan Pachkoria, Beatriz García-Muñoz.   

Abstract

Assigning causality in drug-induced liver injury is challenging particularly when more than one drug could be responsible. We report a woman on long-term therapy with raloxifen who developed acute cholestasis shortly after starting fenofibrate. The picture evolved into chronic cholestasis. We hypothesized that an interaction at the metabolic level could have triggered the presentation of hepatotoxicity after a very short time of exposure to fenofibrate in this patient. The findings of an overexpression of vascular endothelial growth factor in the liver biopsy suggest that angiogenesis might play a role in the persistence of toxic cholestasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16937543      PMCID: PMC4088030          DOI: 10.3748/wjg.v12.i32.5244

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  9 in total

1.  Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study.

Authors:  Jesús Medina; Paloma Sanz-Cameno; Luisa García-Buey; Samuel Martín-Vílchez; Manuel López-Cabrera; Ricardo Moreno-Otero
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

2.  Raloxifene-associated hepatitis.

Authors:  A R Vilches; V Pérez; D E Suchecki
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

3.  [Chronic lesion of the interlobular bile ducts induced by fenofibrate].

Authors:  A Lepicard; A Mallat; E S Zafrani; D Dhumeaux
Journal:  Gastroenterol Clin Biol       Date:  1994

Review 4.  Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Authors:  D B Miller; J D Spence
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

5.  Elevated serum levels of vascular endothelial growth factor are associated with tumor-associated macrophages in primary breast cancer.

Authors:  Luis Vicioso; Francisco J Gonzalez; Martina Alvarez; Nuria Ribelles; Manuel Molina; Antonia Marquez; Lidia Perez; Alfredo Matilla; Emilio Alba
Journal:  Am J Clin Pathol       Date:  2006-01       Impact factor: 2.493

6.  Serum and plasma levels of FGF-2 and VEGF in healthy blood donors.

Authors:  A Larsson; E Sköldenberg; H Ericson
Journal:  Angiogenesis       Date:  2002       Impact factor: 9.596

7.  Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

Authors:  Qing Chen; Jason S Ngui; George A Doss; Regina W Wang; Xiaoxin Cai; Frank P DiNinno; Timothy A Blizzard; Milton L Hammond; Ralph A Stearns; David C Evans; Thomas A Baillie; Wei Tang
Journal:  Chem Res Toxicol       Date:  2002-07       Impact factor: 3.739

8.  [Autoimmune hepatitis induced by fibrates].

Authors:  N Ganne-Carrié; A de Leusse; C Guettier; L Castera; H Levecq; H J Bertrand; Y Plumet; J C Trinchet; M Beaugrand
Journal:  Gastroenterol Clin Biol       Date:  1998-05

9.  Drug-induced liver injury.

Authors:  Neil Kaplowitz
Journal:  Clin Infect Dis       Date:  2004-03-01       Impact factor: 9.079

  9 in total
  9 in total

1.  Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.

Authors:  Patrick Thurner; Christian Nanoff
Journal:  Breast Care (Basel)       Date:  2008-11-25       Impact factor: 2.860

2.  Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).

Authors:  K Pachkoria; M I Lucena; F Ruiz-Cabello; E Crespo; M R Cabello; R J Andrade
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

Review 3.  Risk factors for idiosyncratic drug-induced liver injury.

Authors:  Naga Chalasani; Einar Björnsson
Journal:  Gastroenterology       Date:  2010-04-12       Impact factor: 22.682

Review 4.  Pathogenesis of alcoholic liver disease: the role of nuclear receptors.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2010-05

Review 5.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.

Authors:  Raúl-J Andrade; Mercedes Robles; Alejandra Fernández-Castañer; Susana López-Ortega; M-Carmen López-Vega; M-Isabel Lucena
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

6.  Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  J Biol Chem       Date:  2009-01-27       Impact factor: 5.157

7.  Identification and Characterization of Fenofibrate-Induced Liver Injury.

Authors:  Jawad Ahmad; Joseph A Odin; Paul H Hayashi; Naga Chalasani; Robert J Fontana; Huiman Barnhart; Elizabeth T Cirulli; David E Kleiner; Jay H Hoofnagle
Journal:  Dig Dis Sci       Date:  2017-11-08       Impact factor: 3.199

8.  Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Authors:  Paola Nicoletti; Guruprasad P Aithal; Einar S Bjornsson; Raul J Andrade; Ashley Sawle; Marco Arrese; Huiman X Barnhart; Emmanuelle Bondon-Guitton; Paul H Hayashi; Fernando Bessone; Alfonso Carvajal; Ingolf Cascorbi; Elizabeth T Cirulli; Naga Chalasani; Anita Conforti; Sally A Coulthard; Mark J Daly; Christopher P Day; John F Dillon; Robert J Fontana; Jane I Grove; Pär Hallberg; Nelia Hernández; Luisa Ibáñez; Gerd A Kullak-Ublick; Tarja Laitinen; Dominique Larrey; M Isabel Lucena; Anke H Maitland-van der Zee; Jennifer H Martin; Mariam Molokhia; Munir Pirmohamed; Elizabeth E Powell; Shengying Qin; Jose Serrano; Camilla Stephens; Andrew Stolz; Mia Wadelius; Paul B Watkins; Aris Floratos; Yufeng Shen; Matthew R Nelson; Thomas J Urban; Ann K Daly
Journal:  Gastroenterology       Date:  2016-12-30       Impact factor: 22.682

Review 9.  Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury.

Authors:  Aida Ortega-Alonso; Camilla Stephens; M Isabel Lucena; Raúl J Andrade
Journal:  Int J Mol Sci       Date:  2016-05-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.